The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19.
NPJ Prim Care Respir Med
; 32(1): 35, 2022 09 21.
Article
in English
| MEDLINE | ID: covidwho-2036825
ABSTRACT
Early in the COVID-19 pandemic, anecdotal reports emerged suggesting non-steroidal anti-inflammatory drugs (NSAIDs) may increase susceptibility to infection and adversely impact clinical outcomes. This narrative literature review (March 2020-July 2021) attempted to clarify the relationship between NSAID use and COVID-19 outcomes related to disease susceptibility or severity. Twenty-four relevant publications (covering 25 studies) reporting original research data were identified; all were observational cohort studies, and eight were described as retrospective. Overall, these studies are consistent in showing that NSAIDs neither increase the likelihood of SARS-CoV-2 infection nor worsen outcomes in patients with COVID-19. This is reflected in current recommendations from major public health authorities across the world, which support NSAID use for analgesic or antipyretic treatment during COVID-19. Thus, there is no basis on which to restrict or prohibit use of these drugs by consumers or patients to manage their health conditions and symptoms during the pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antipyretics
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
NPJ Prim Care Respir Med
Year:
2022
Document Type:
Article
Affiliation country:
S41533-022-00300-z
Similar
MEDLINE
...
LILACS
LIS